Company Overview of BiPar Sciences, Inc.
BiPar Sciences, Inc., a biopharmaceutical company, engages in developing and commercializing tumor-selective drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded in 2002 and is headquartered in Brisbane, California. As of April 27, 2009, BiPar Sciences, Inc. operates as a subsidiary of Sanofi.
1000 Marina Boulevard
Brisbane, CA 94005
Founded in 2002
Key Executives for BiPar Sciences, Inc.
Similar Private Companies By Industry
|P2D, Inc.||United States|
|Viva Life Science, Inc.||United States|
|Biosyntrx, Inc.||United States|
|Pharmion LLC||United States|
|Bio-Botanica, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Greater Houston Partnership||United States|
Post a JobJobs
- Tampa, FL | Bristol-Myers SquibbPosted: Nov 13
- Baltimore, MD | AstraZenecaPosted: Dec 04
- San Francisco, CA | JobvertisePosted: Nov 30
- Princeton, NJ | RGPPosted: Nov 27
Sponsored Financial Commentaries
To contact BiPar Sciences, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.